Literature DB >> 27873177

Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria.

Seiko Iki1, Kazuyuki Ohgi2, Kenshi Suzuki3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27873177     DOI： 10.1007/s12185-016-2144-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  3 in total

Review 1.  Physiology and pathophysiology of heme: implications for kidney disease.

Authors:  Michal J Tracz; Jawed Alam; Karl A Nath
Journal:  J Am Soc Nephrol       Date:  2007-01-17       Impact factor: 10.121

2.  Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.

Authors:  Yuzuru Kanakura; Kazuma Ohyashiki; Tsutomu Shichishima; Shinichiro Okamoto; Kiyoshi Ando; Haruhiko Ninomiya; Tatsuya Kawaguchi; Shinji Nakao; Hideki Nakakuma; Jun-ichi Nishimura; Taroh Kinoshita; Camille L Bedrosian; Marye Ellen Valentine; Gus Khursigara; Keiya Ozawa; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2011-01-12       Impact factor: 2.490

3.  The kidney in paroxysmal nocturnal haemoglobinuria: MRI findings.

Authors:  J Rimola; J Martín; J Puig; A Darnell; A Massuet
Journal:  Br J Radiol       Date:  2004-11       Impact factor: 3.039
  3 in total
  1 in total

1.  Even mild hemolysis in paroxysmal nocturnal hemoglobinuria could severely compromise the quality of life due to long-term sustained intolerant fatigue.

Authors:  Kazuya Sakai
Journal:  Leuk Res Rep       Date:  2020-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.